본문으로 건너뛰기
← 뒤로

Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer.

2/5 보강
The Urologic clinics of North America 📖 저널 OA 2.3% 2022: 0/1 OA 2024: 0/1 OA 2025: 0/3 OA 2026: 0/32 OA 2022~2026 2026 Vol.53(2) p. 233-242 Prostate Cancer Diagnosis and Treatm
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29
OpenAlex 토픽 · Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Urinary Bladder and Prostate Research

Penukonda S, Hyams E, Pareek G, Santopietro A, Carneiro B

📝 환자 설명용 한 줄

High-risk localized prostate cancer (HR-PCa) presents a substantial risk of recurrence and progression despite definitive local treatment.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Suhas Penukonda, Elias Hyams, et al. (2026). Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer.. The Urologic clinics of North America, 53(2), 233-242. https://doi.org/10.1016/j.ucl.2026.02.006
MLA Suhas Penukonda, et al.. "Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer.." The Urologic clinics of North America, vol. 53, no. 2, 2026, pp. 233-242.
PMID 41986019 ↗

Abstract

High-risk localized prostate cancer (HR-PCa) presents a substantial risk of recurrence and progression despite definitive local treatment. This article evaluates the evolving role of neoadjuvant and adjuvant therapies, including androgen deprivation therapy, second-generation androgen receptor pathway inhibitors, and chemotherapy. While neoadjuvant strategies improve pathologic responses, survival benefits remain unproven. Adjuvant therapy is increasingly individualized, with early salvage radiotherapy favored over routine adjuvant radiotherapy based on recent trial data. Ongoing studies, molecular profiling, and advanced imaging aim to refine patient selection and personalize treatment, balancing oncologic control with quality of life in the management of HR-PCa.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반